Follow The Filings

IBO Impact BioMedical

Impact BioMedical earnings company data as of 4:00 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IBO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IBO insider trades
  • None no insider bought on the open market
  • $60K sold by 3 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Dss, Inc. 10% owner
    Sale
    $1,686 906 shares at $1.86 0.2% of stake
    Traded Sep 22–24 Filed Sep 24
    ↗
  2. Todd D Macko CFO
    Sale
    $25K 45,000 shares at $0.5600 23% of stake
    Traded Mar 25–27 Filed Mar 30
    ↗
  3. Jason Grady Director
    Sale
    $33K 50,000 shares at $0.6500 17% of stake
    Traded Mar 23 Filed Mar 25
    ↗
  4. Dss, Inc. 10% owner
    Sale
    $88K 161,000 shares at $0.5500 23% of stake
    Traded May 22–27 Filed Jan 6
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.03,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
10-Q Filing Doc
10-K Filing Doc
8-K 1.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
DEF 14A Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13D — Filing Doc
8-K 1.01,9.01 Filing Doc
10-K Period Dec 31, 2024 Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Period Sep 30, 2024 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.